Characterization of bortezomib-adapted I-45 mesothelioma cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Zhang, Lidong ^a   Littlejohn, James E ^a   Cui, Yu ^a,b   Cao, Xiaobo ^a   Peddaboina, Chander ^a   Smythe, W Roy ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b TIANJIN UNION MEDICAL CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEASOME; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; PROTEIN PSMB5; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BAX INHIBITING PEPTIDE, BIP; BAX-INHIBITING PEPTIDE, BIP; BORONIC ACID DERIVATIVE; DDIT3 PROTEIN, HUMAN; OLIGOPEPTIDE; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; PYRAZINE DERIVATIVE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EXPOSURE; ENDOPLASMIC RETICULUM; GENE INDUCTION; HUMAN; HUMAN CELL; MESOTHELIOMA; MITOCHONDRIAL MEMBRANE; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SYNTHESIS INHIBITION; UBIQUITINATION; ANIMAL; CELL SEPARATION; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; METABOLISM; TUMOR CELL LINE; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; MESOTHELIOMA; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR CHOP; TRANSFECTION; UNFOLDED PROTEIN RESPONSE;

EID: 77952248475     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-110     Document Type: Article

References (27)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4(5):349-360. 10.1038/nrc1361, 15122206.
2. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5(5):417-421. 10.1016/S1535-6108(04)00120-5, 15144949.
3. Sanchez-Serrano I. Success in translational research: lessons from the development of bortezomib. Nat Rev Drug Discov 2006, 5(2):107-114. 10.1038/nrd1959, 16518378.
4. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007, 13(19):5942-5951. 10.1158/1078-0432.CCR-07-0536, 17908991.
5. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008, 14(6):1649-1657. 10.1158/1078-0432.CCR-07-2218, 18347166.
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348(26):2609-2617. 10.1056/NEJMoa030288, 12826635.
7. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Blade J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110(10):3557-3560. 10.1182/blood-2006-08-036947, 17690257.
8. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA. An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 2008, 8(3):140-145. 10.3816/CLM.2008.n.016, 18650176.
9. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61(7):3071-3076.
10. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277(19):16639-16647. 10.1074/jbc.M200360200, 11872748.
11. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107(12):4907-4916. 10.1182/blood-2005-08-3531, 1895817, 16507771.
12. Williams SA, McConkey DJ. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 2003, 63(21):7338-7344.
13. Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther 2008, 7(6):1647-1655. 10.1158/1535-7163.MCT-07-2444, 2534142, 18566236.
14. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005, 65(14):6282-6293. 10.1158/0008-5472.CAN-05-0676, 16024630.
15. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003, 63(19):6174-6177.
16. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008, 103(1):270-283. 10.1002/jcb.21405, 17516511.
17. Lu S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L, Wang J. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 2008, 36(10):1278-1284. 10.1016/j.exphem.2008.04.013, 18562081.
18. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van ZI, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112(6):2489-2499. 10.1182/blood-2007-08-104950, 18565852.
19. Ruckrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft HS, Kalbacher H, Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 2009, 23(6):1098-1105. 10.1038/leu.2009.8, 19225532.
20. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 2001, 3(3):283-288. 10.1038/35060076, 11231578.
21. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature 1998, 392(6676):618-622. 10.1038/33443, 9560160.
22. Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006, 5(7):745-748.
23. Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000, 275(33):25255-25261. 10.1074/jbc.M909826199, 10837489.
24. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 2006, 13(3):363-373. 10.1038/sj.cdd.4401817, 16397583.
25. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008, 11(4-5):164-179. 10.1016/j.drup.2008.08.002, 18818117.
26. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004, 24(22):9695-9704. 10.1128/MCB.24.22.9695-9704.2004, 525474, 15509775.
27. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther 2002, 9(18):1262-1270. 10.1038/sj.gt.3301797, 12215894.